Analysts Issue Forecasts for AEON Biopharma Q3 Earnings

AEON Biopharma, Inc. (NASDAQ:AEON) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of AEON Biopharma in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.07) for the quarter. HC Wainwright has a “Buy” rating and a $1.20 price objective on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.77) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS and Q4 2027 earnings at ($0.06) EPS.

AEON has been the subject of several other research reports. Lake Street Capital started coverage on AEON Biopharma in a research note on Thursday, July 30th. They set a “buy” rating and a $1.00 price target for the company. Zacks Research upgraded shares of AEON Biopharma to a “hold” rating in a research report on Wednesday, May 27th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1.10.

AEON Biopharma Trading Down 4.1%

Shares of AEON stock opened at $0.24 on Monday. The company has a market capitalization of $6.20 million, a P/E ratio of 1.36 and a beta of 0.66. The business’s 50 day moving average is $0.47 and its two-hundred day moving average is $0.80. AEON Biopharma has a twelve month low of $0.22 and a twelve month high of $1.45.

Institutional Investors Weigh In On AEON Biopharma

A hedge fund recently raised its stake in AEON Biopharma stock. Geode Capital Management LLC grew its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,134 shares of the company’s stock after purchasing an additional 13,061 shares during the period. Geode Capital Management LLC owned approximately 0.51% of AEON Biopharma worth $66,000 at the end of the most recent reporting period. 22.78% of the stock is owned by institutional investors and hedge funds.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical?stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.